[go: up one dir, main page]

AU1128801A - Agents for treating human diseases, especially for treating tumors such as colonic cancers and melanomas or for regenerating tissue and promoting hair growth - Google Patents

Agents for treating human diseases, especially for treating tumors such as colonic cancers and melanomas or for regenerating tissue and promoting hair growth

Info

Publication number
AU1128801A
AU1128801A AU11288/01A AU1128801A AU1128801A AU 1128801 A AU1128801 A AU 1128801A AU 11288/01 A AU11288/01 A AU 11288/01A AU 1128801 A AU1128801 A AU 1128801A AU 1128801 A AU1128801 A AU 1128801A
Authority
AU
Australia
Prior art keywords
treating
melanomas
agents
hair growth
human diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU11288/01A
Inventor
Walter Birchmeier
Jens-Peter Von Kries
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Max Delbrueck Centrum fuer Molekulare in der Helmholtz Gemeinschaft
Original Assignee
Max Delbrueck Centrum fuer Molekulare in der Helmholtz Gemeinschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Delbrueck Centrum fuer Molekulare in der Helmholtz Gemeinschaft filed Critical Max Delbrueck Centrum fuer Molekulare in der Helmholtz Gemeinschaft
Publication of AU1128801A publication Critical patent/AU1128801A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention relates to agents for treating human diseases which are based on substances that specifically influence the binding of beta -catenin on LEF-1/TCF- transcription factors, APC or conductin/axin. The invention particularly relates to the identification and use of hydrophobic pockets on the molecular surface in the proximity of the essential binding points for the binding partners of ss-catenin with the aim of optimizing these substances. The invention also relates to the use of the substances, preferably for treating tumors such as colonic cancers and melanomas or for regenerating tissue and promoting hair growth.
AU11288/01A 1999-09-16 2000-09-07 Agents for treating human diseases, especially for treating tumors such as colonic cancers and melanomas or for regenerating tissue and promoting hair growth Abandoned AU1128801A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19944404 1999-09-16
DE19944404A DE19944404A1 (en) 1999-09-16 1999-09-16 Agents for the therapy of human diseases, in particular for the therapy of tumors such as colon carcinomas and melanomas or for tissue regeneration and promotion of hair growth
PCT/DE2000/003104 WO2001019353A2 (en) 1999-09-16 2000-09-07 Agents for treating human diseases, especially for treating tumors such as colonic cancers and melanomas or for regenerating tissue and promoting hair growth

Publications (1)

Publication Number Publication Date
AU1128801A true AU1128801A (en) 2001-04-17

Family

ID=7922237

Family Applications (1)

Application Number Title Priority Date Filing Date
AU11288/01A Abandoned AU1128801A (en) 1999-09-16 2000-09-07 Agents for treating human diseases, especially for treating tumors such as colonic cancers and melanomas or for regenerating tissue and promoting hair growth

Country Status (7)

Country Link
EP (1) EP1214345B1 (en)
JP (1) JP2003509364A (en)
AT (1) ATE286071T1 (en)
AU (1) AU1128801A (en)
CA (1) CA2388383A1 (en)
DE (3) DE19944404A1 (en)
WO (1) WO2001019353A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003006447A2 (en) * 2001-07-09 2003-01-23 Pharmacia Italia Spa Interaction inhibitors of tcf-4 with beta-catenin
CA2494240A1 (en) * 2002-08-06 2004-02-12 Exelixis, Inc. Maxs as modifiers of the axin pathway and methods of use
EP1977747A1 (en) * 2007-04-05 2008-10-08 Max-Delbrück-Centrum Adaptive cardiac remodeling by beta-catenin downregulation
WO2008122440A2 (en) * 2007-04-05 2008-10-16 Max-Delbrück-Centrum für Molekulare Medizin Remedy for the treatment of cardio-vascular diseases or disorders
CN108066345A (en) * 2016-11-14 2018-05-25 武汉华杰世纪生物医药有限公司 A kind of compound with antitumor action

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6866198A (en) * 1997-03-24 1998-10-20 Onyx Pharmaceuticals, Inc. Compositions and methods for diagnosing/treating disease based on beta-catenin/transcription factor interactions
WO1999042481A2 (en) * 1998-02-21 1999-08-26 Max-Delbrück-Centrum für Molekulare Medizin AGENTS FOR TREATING HUMAN ILLNESSES BASED ON β-CATENIN, AND THE PRODUCTION AND USE THEREOF

Also Published As

Publication number Publication date
JP2003509364A (en) 2003-03-11
DE50009133D1 (en) 2005-02-03
EP1214345B1 (en) 2004-12-29
WO2001019353A3 (en) 2002-03-28
DE19944404A1 (en) 2001-03-22
ATE286071T1 (en) 2005-01-15
DE10082729D2 (en) 2002-01-24
EP1214345A2 (en) 2002-06-19
CA2388383A1 (en) 2001-03-22
WO2001019353A2 (en) 2001-03-22

Similar Documents

Publication Publication Date Title
HK1133017A1 (en) Specific binding agents of human angiopoietin-2
WO2004050707A3 (en) Tumor-specific recognition molecules
AU2002351196A1 (en) Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
WO2002046477A3 (en) Endogenous retroviruses up-regulated in prostate cancer
WO2002080754A3 (en) Methods for using annexin for detecting cell death in vivo and treating associated conditions
MXPA04001524A (en) Rapamycin 29-enols.
HK1022301A1 (en) Conjugates of cisdocosahexaenoic acid and paclitaxel
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
HK1080840A1 (en) Arylcarbonylpiperazines and heteroarylcarbonylpiperazines and the use thereof for treating benign and malignant tumour diseases
PT967987E (en) COMPOSITIONS FOR THE TREATMENT OF TUMORS CONTAINING TUBARAO CARTILAGE EXTRACTS AND ANTINEOPLASTIC AGENTS
ATE257152T1 (en) N-BENZYL-3-INDENYLACEAMIDE DERIVATIVE FOR THE TREATMENT OF NEOPLASIA
ES2161655B1 (en) PROCEDURE TO DETERMINE THE INVASIVE AND METASTASSIC CAPACITY OF AN EPITELIAL TUMOR THROUGH THE USE OF SNAIL.
DE69927688D1 (en) Antiviral agent in combination with radiotherapy for use in the treatment of cancer
AU1128801A (en) Agents for treating human diseases, especially for treating tumors such as colonic cancers and melanomas or for regenerating tissue and promoting hair growth
CY1106525T1 (en) THERAPEUTIC TREATMENT WITH hCG FOR THE TREATMENT OF METASTATIC BREAST CANCER
BR9808958A (en) 1,2,4-benzotriazine oxide formulations
DE69927714D1 (en) 19-NOR-VITAMIN D3 DERIVATIVES WITH CALCIUM MIRROR INCREASING EFFECT
DE69835828D1 (en) MUC-1 DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER ASSOCIATED MUC-1 MUCIN-INDUCED IMMUNOSUPPRESSION
AU1991901A (en) Pharmaceutical composition for treating and preventing human tumors, which express the tumor antigen mucin and/or the carcinoembryonic antigen (cea), and the use thereof
WO2006010838A3 (en) Products containing at least one anticancer active principle with low diffusion and an immunostimulatory active principle
IL164356A (en) Use of alpha- bromo or alpha-chloro acryloyl distamycin derivatives in the preparation of medicaments for treating cancer
AU2001291256A1 (en) Methods and compositions for the identification, assessment and therapy of human cancers
UA49216A (en) Remedy for treating complication following resection of malignant tumors of skin
CY1111320T1 (en) CRIPTO SPECIAL ANTIBODIES
TW200635953A (en) Specific binding agents of human angiopoietin-2

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase
TH Corrigenda

Free format text: IN VOL 15, NO 27, PAGE(S) 5693-5698 UNDER THE HEADING APPLICATIONS LAPSED, REFUSED OR WITHDRAWN PLEASE DELETE ALL REFERENCE TO APPLICATION NO. 11288/01 AND 11290/01

MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase